Free Trial
NYSE:TFX

Teleflex Q2 2025 Earnings Report

Teleflex logo
$120.03 +1.10 (+0.92%)
Closing price 03:59 PM Eastern
Extended Trading
$119.73 -0.30 (-0.25%)
As of 04:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Teleflex EPS Results

Actual EPS
N/A
Consensus EPS
$3.36
Beat/Miss
N/A
One Year Ago EPS
N/A

Teleflex Revenue Results

Actual Revenue
N/A
Expected Revenue
$771.53 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Teleflex Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Thursday, July 31, 2025
Conference Call Time
8:00AM ET

Conference Call Resources

Teleflex Earnings Headlines

Teleflex closes deal with BIOTRONIK
Trump’s Exec Order #14154 could be a “Millionaire-Maker”
Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape.
See More Teleflex Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Teleflex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Teleflex and other key companies, straight to your email.

About Teleflex

Teleflex (NYSE:TFX) (NYSE: TFX) is a global provider of critical care medical devices and technologies, serving healthcare professionals in more than 150 countries. The company’s product portfolio spans three primary segments—Surgical, Anesthesia, and Respiratory—offering a broad array of solutions designed for minimally invasive surgery, airway management, interventional cardiology, and vascular access. Teleflex’s brands include recognized names such as Arrow® catheters, LMA® (laryngeal mask airway) devices, and PleurX® drainage systems, which are used in hospitals, outpatient facilities, and home care settings worldwide.

In the Surgical segment, Teleflex delivers instrumentation, access devices, and consumables that facilitate urology, interventional cardiology, and general surgery procedures. The Anesthesia segment focuses on airway management, with a suite of products that range from endotracheal tubes to video laryngoscopes and supraglottic airway devices. Teleflex’s Respiratory division develops catheters, drainage solutions, and respiratory monitoring equipment that support patient care in critical and acute settings. Across all segments, the company emphasizes product innovation, regulatory compliance, and partnerships with clinicians to address evolving clinical needs.

Founded in 1943, Teleflex initially produced precision-machined components for aviation and other industrial markets. Over the decades, the company shifted its strategic focus toward healthcare through organic growth and targeted acquisitions. Key milestones include the acquisition of Deknatel in 1998, which bolstered its urology portfolio, and the purchase of RITE Aid’s respiratory care business in the early 2000s. Recent expansions have strengthened Teleflex’s presence in Europe and Asia-Pacific, establishing a network of manufacturing facilities, R&D centers, and sales offices that support localized product development and market access.

Teleflex is led by President and Chief Executive Officer Liam J. Kelly, who joined the company in 2018 and has driven efforts to streamline operations and enhance the global product pipeline. The senior leadership team combines deep clinical expertise and commercial acumen to guide strategic planning, quality initiatives, and sustainability programs. Headquartered in Wayne, Pennsylvania, Teleflex operates with a commitment to improving patient outcomes and delivering value to healthcare providers through continuous innovation and service excellence.

View Teleflex Profile

More Earnings Resources from MarketBeat